GT Biopharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum

GT Biopharma, Inc.

Nasdaq letter on Nov 21, 2024: stockholders' equity fell below $2.5M required for continued listing.
Company does not meet market value of listed securities or net income alternatives.
Must submit compliance plan by Jan 6, 2025; Nasdaq may grant up to 180-day extension.
If plan not accepted, Company may appeal to Nasdaq Hearings Panel.
Stock continues trading under GTBP; no assurance of regaining compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.